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Objectives: The current prevalence of Total Hip Replacement (THR) in adult 
patients in Slovakia ranges in about 5 200 cases per year with expenditures about 
10.545.600 € . The THR has a great impact on the quality of life (QoL) and the physi-
cal ability too. Till now in the Slovak Republic was not realised the study like this 
one. MethOds: 118 patients, 59 men and 59 women, with THR were studied. The 
average age was 62,24 y., the average duration of illness was 7,75 y. and the average 
waiting time to surgery was 0,73 y. QoL and the taking care about himself (TCaH) 
was evaluated after THR on the numeric scale from 0 to 10 (0 for the worst, 10 for the 
best) and pain (0 for the best, 10 for the worst) by patients themselves Results: QoL 
has increased from 4,24 to 6,30 after THR. The ability to take care about himself has 
decreased from 6,38 to 3,45 after THR. Pain has decreased from 7,85 to 3,32 after THR, 
and after spa stay from 3,04 to 2,03. The loss of money in productive age patients 
was 216,63 € . The score of physical health by SF 36 questionnaire was 50,94 points 
and score of mental health was 65,41 points, the average score was 57,98 points. 35 
patients from 45 patients were able to come back to work after THR. cOnclusiOns: 
THR has a great impact on QoL, pain and on the TCaH too. There was not statistical 
difference between men and women in all evaluated parameters. The early/earlier 
made THR could have an important influence on better QoL and pain development. 
There is a good correlation between results from numeric scale and SF 36.
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ObjectivOs: analizar el comportamiento de pacientes con enfermedad crónica 
osteoarticular afiliados a una aseguradora colombiana. MetOdOlOgíAs: a partir 
de la información de usos y consumos de una aseguradora colombiana para el año 
2013, se identificaron todos los pacientes que habían sido atendidos al menos tres 
veces por servicios ambulatorios o con un egreso hospitalario con diagnósticos aso-
ciados a esta enfermedad, que incluyen diferentes tipos de artritis y osteoartrosis, 
y que fueron identificados de acuerdo con los códigos de diagnóstico. Los pacientes 
fueron analizados en función de sus variables demográficas, uso de servicios, costos 
y comorbilidades. ResultAdOs: se estimó una prevalencia del 3,75% de enferme-
dad osteoarticular sobre la población total con una edad promedio de 50,2 años, 
siendo el 58,93% mujeres. Los pacientes tienen un costo promedio anual en servicios 
con cargo al plan obligatorio de salud de $1.369.493,20 pesos colombianos, que en 
total por la carga de pacientes significa el 12,28% del costo total para el asegurador. 
El 19,39% de estos presenta comorbilidades, siendo diabetes, enfermedad cardio-
vascular y enfermedades digestivas crónicas las más frecuentes. Además, se estimó 
que el costo promedio aumenta 1,5 veces a medida que se asocia una comorbilidad 
adicional. cOnclusiOnes: el grupo de riesgo por enfermedad osteoarticular se 
convierte en un grupo de interés para la gestión del aseguramiento, en especial por 
la cantidad de pacientes identificados, lo que genera una alta carga de enfermedad. 
En este caso, esta carga se presenta especialmente en mujeres adultas, y sus costos 
se potencian con comorbilidades, lo cual hace más importante el control y gestión 
de la progresión.
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Objectives: Ankylosing spondylitis (AS) is a progressive, incurable rheumatologic 
disease with worldwide prevalence of 0.1-0.5%. Since January 2012, the Brazilian 
Agency for Supplementary Healthcare (ANS-Agência Nacional de Saúde Suplementar) 
declared the coverage of intravenous biological drugs (BD) mandatory for patients 
with AS, rheumatoid arthritis, psoriatic arthritis and Crohn’s disease in the private 
healthcare system (PHS). This study presents real-word data on the patterns-of-care 
for AS in Brazilian PHS. MethOds: We retrieved all requests of BD for patients with 
AS submitted between January/2012-January/2015 on Evidências-Kantar Health pri-
vate market administrative claims database. After patient de-identification, data 
on diagnosis, type of drug, and line-of-treatment were collected. Results: BD was 
requested for 46 patients, 16 males (34.8%) and 30 females (65.2%), mean age of 43.7 
years. Drugs requested were: infliximab (39.1%), adalimumab (21.7%), golimumab 
(19.6%), etanercept (17.4%) and rituximab (2.2%). Most patients (73.9%) were on first-
line treatment with BD, 23.9% on second and 2.2% on third-line. Reasons for change 
in medication were: unsatisfactory response (75%) and adverse events (25%). Based on 
available information, diagnosis of AS couldn’t be confirmed for all patients. For 52.2% 
AS was the most likely diagnosis, other possible diagnoses were: primary sacroiliitis 
(17.4%), degenerative spine disease (4.3%), unspecific lumbar pain (4.3%), enteropathic 
arthritis (4.3%), Reiter’s syndrome (2.2%) and seronegative arthropathy (2.2%). In 13% 
of the cases, lack of information precluded diagnosis. In 4 of 16 cases in which AS 
was not the most likely diagnosis, patients were already on 2nd or 3rdline treatments 
due to unsatisfactory response. cOnclusiOns: Choice of BD followed international 
guidelines for AS. However, almost half the patients could not have diagnosis of AS 
confirmed, even tough some were already on 2nd or 3rd line therapy with BD. PHS 
must emphasize the correct use of diagnostic criteria before patients are put on 
unnecessary treatment with BD.
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ObjetivOs: O programa Desfechos caracteriza-se como um centro de coleta de 
dados que tem como principal objetivo mensurar o desfecho clínico e qualidade de 
vida periódica de pacientes pós alta hospitalar. O programa trabalha em conjunto 
com os Programas Integrados na disponibilização de informações com foco nos 
indicadores de resultado. Este trabalho irá apresentar o Programa Desfechos e os 
dados coletados (jan/2011-jan/2015), em diversos períodos de seguimento pós alta 
hospitalar. MétOdOs: Estudo transversal, retrospectivo, a partir da análise quan-
titativa dos dados. Neste estudo foram realizadas ligações telefônicas utilizando o 
instrumento EQ-5D para medir qualidade de vida. O método utilizado foi o Time 
Trade-Off (TTO). O estudo foi realizado no Hospital Israelita Albert Einstein (HIAE), 
um hospital geral, privado, de alta complexidade. ResultAdOs: Realizamos 16.479 
ligações telefônicas e obtivemos 10.985 (67%) de contatos com sucesso. Na coleta dos 
dados de qualidade de vida, os pacientes apresentaram a média de TTO: 0,546 antes 
do procedimento ou alta hospitalar e após 6 meses, apresentou TTO:0,814. No follow 
up coletamos 268 (9%) informações de óbitos. Os principais motivos de censuras 
foram: insucesso após 4 tentativas (30%); dados cadastrais desatualizados (1%) e 
recusas (2%). cOnclusões: É essencial que as organizações de saúde avaliem de 
maneira eficaz os desfechos clínicos e estado funcional de seus pacientes após alta 
hospitalar. Desta maneira será possível avaliar a qualidade da assistência prestada, 
identificar as reais necessidades de seus pacientes e assim, melhorar a utilização 
dos recursos e sistemas de saúde.
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Objectives: Clinical trials for osteoarthritis (OA) are increasingly using electronic 
methods to collect patient-reported outcomes (ePRO). As use of this technology 
increases, it is important to consider patient preference in questionnaire design. 
The purpose of this study was to determine optimal use/compliance for subjects 
completing daily ePRO diaries on handheld devices. MethOds: 104 subjects with 
OA were surveyed in the US. Subjects were asked to assume that they were using a 
handheld electronic device to complete questionnaires in a clinical trial. Subjects 
were given examples and asked about their preferences for improving their com-
pliance and engagement in the technology. Results: Subjects were 37 to 90 years 
old and 58% female. 62% reported that they would like to see a “thank you” screen 
at the end of each questionnaire. 78% thought it would be helpful or necessary to 
regularly receive a graph to track and monitor their symptoms. 92% preferred to see 
their progress as they completed a questionnaire. 70% of subjects said they would 
like the first screen of the questionnaire on the device, summarizing question-
naire length/estimated completion time. Subjects were asked if being informed 
by the device that their compliance was below expectations would motivate them 
to complete a daily questionnaire. The majority of subjects (76-80%) indicated 
that this information would motivate them, 13-15% indicated this would have no 
impact on their motivation, and less than 9% indicated such messaging would be 
discouraging. cOnclusiOns: Subjects with OA were motivated by knowing their 
compliance in completing a daily questionnaire. Specifically, subjects preferred a 
diary screen summarizing questionnaire length/completion time, tracking their 
progress through a questionnaire, and “thank you” messages upon questionnaire 
completion. Subjects were interested in tracking and monitoring their health status. 
Investigators should consider including these design elements for use with ePRO 
assessments in clinical trials.
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Fondo Nacional de Recursos (FNR) creado por ley para asegurar el acceso de toda 
la población a un conjunto de prestaciones médicas de alta especialización e 
impacto económico. Basándose en la calidad, asegura la viabilidad económica 
de sus prestaciones. Adquiere especial relevancia el seguimiento de la situación 
de los pacientes que han recibido financiación del FNR para la realización de 
actos médicos o medicamentos fuera del listado de cobertura priorizada a su 
cargo, como consecuencia de una sentencia judicial que impone al FNR dicha 
prestación.ObjectivOs: Analizar coberturas adjudicadas judicialmente. 
Determinar si corresponden a cobertura no priorizada. Verificar el cumplimiento 
de las sentencias de condena; el tiempo transcurrido entre la adjudicación y 
la cobertura; y la sobrevida de los mismos. MetOdOlOgíAs: Estudio descrip-
tivo a través de encuesta telefónica a los pacientes con cobertura judicialmente 
determinada, entre 2007- 2014. Sin criterios de exclusión. ResultAdOs: En el 
período se cubrieron 56 solicitudes, 5% no ubicados. 93% sector privado, 95% 
Medicamentos: Interferón Beta 35,7% (n= 20), Sorafenib 27.5% (21), Bevacizumab 
y Temozolamida 5.4% (3). Patologías Esclerosis Múltiple y Hepatocarcinoma 35.7% 
(20), tumores SNC 7.1% (4). La sobrevida de los pacientes fue de 70%. La mortalidad 
en Hepatocarcinomas fue 94.1% y la sobrevida de 8 meses. En los pacientes con EM 
fue de 4.34 años, no fallecidos. cOnclusiOnes: La totalidad de las solicitudes se 
encontraban fuera de la normativa del FNR, no contempladas por el FTM ni PIAS. 
La cobertura fue inmediata a la sentencia, cumpliendo los aspectos técnicos y 
médicos. Entrevistados mostraron interés y disponibilidad a participar en estu-
dios de estas características. La experiencia demostró la pertinencia de incluir 
seguimiento periódico a pacientes cubiertos judicialmente.
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